↑ トップへ ← 戻る

 Drug(薬物リスト) ALL | DrugBank 

   e.g. "Sirolimus", "アダリムマブ"    Synonyms (Drugs) were also searched for.

A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z other

87 / 1,666 drugs found* Show info (disease name, etc.) on mouse-over.
 No.   DrugBank   薬物名(臨床試験情報から抽出)   KEGG DRUG  KEGG GENES  KEGG PATHWAY   指定難病告示番号
 1   Abatacept  27件: Abatacept; Abatacept injection; Bms 188667 (abatacept); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept placebo; Abatacept prefilled syringe; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; Abatacept subcutaneous; Abatacept sc; Abatacept (aba);   D03203   2件: CD80, CD86   3件: Cell adhesion molecules (CAMs), Intestinal immune network for IgA production, Rheumatoid arthritis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300
 2   Adenosine  6件: 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; 2-chloro-2'-deoxyadenosine, 2cda; 2-chloro-2’-deoxyadenosine (2-cda); Adenosine; Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv);   D00045   4件: ADORA1, ADORA2A, ADORA2B, ADORA3   2件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction   5件:
13,
46,
53,
58,
65
 3   Aldesleukin  3件: Aldesleukin; Low-dose aldesleukin (proleukin®); Interleukin-2 (aldesleukin).;   D00748   3件: IL2RA, IL2RB, IL2RG   3件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Pathways in cancer   4件:
2,
49,
65,
97
 4   Alefacept  1件: Alefacept;   D02800   1件: CD58   1件: Cell adhesion molecules (CAMs)   6件:
37,
60,
65,
164,
284,
285
 5   Alemtuzumab  18件: Alemtuzumab; Alemtuzumab (gz402673); Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab (campath); Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab and rituximab; Alemtuzumab, rituximab; Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D02802   -   -   17件:
13,
15,
19,
20,
46,
49,
51,
60,
63,
65,
85,
96,
164,
234,
284,
285,
326
 6   Amlodipine  4件: Amlodipine; Amlodipine gel; Calcium channel blockers (amlodipine, azelnidipine); Amlodipine (drug);   D00615
 D02914
 D07450 
 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   4件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction   4件:
51,
65,
67,
298
 7   Anakinra  8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra and peg stnf-r1; Kineret® (anakinra); Response to anakinra associated with methotrexate; Anakinra / kineret; Kineret® or anakinra;   D02934   2件: IL1R1, IL1R2   2件: Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels   17件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
65,
84,
86,
106,
107,
266,
299
 8   Azathioprine  33件: Azathioprine; Prednisone - azathioprine; Azathioprine (aza); Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Azathioprine 25 mg; Continuation of azathioprine; Cyclophosphamide-prednisone-azathioprine; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine; Azathioprine/prednisone; 5-asa, prednisone, azathioprine or remicade; Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Early immunosuppressants (azathioprine, methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Azathioprine and allopurinol; Overencapsulated azathioprine (imuran) 50 mg tablet; Products containing azathioprine or 6-mercaptopurine; Azathioprine or mycophenolate mofetil;   D00238
 D03033 
 -   -   18件:
11,
13,
19,
35,
42,
43,
44,
45,
46,
49,
65,
66,
85,
94,
95,
96,
97,
162
 9   Azelnidipine  2件: Azelnidipine; Calcium channel blockers (amlodipine, azelnidipine);   D01145   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   4件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Cardiac muscle contraction, Vascular smooth muscle contraction   1件:
65
 10   Basiliximab  1件: Basiliximab;   D03058   1件: IL2RA   4件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, JAK-STAT signaling pathway   7件:
2,
50,
65,
66,
97,
222,
228
 11   Benznidazole  1件: Benznidazole;   D02489   -   -   1件:
65
 12   Betamethasone  6件: Betamethasone; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Betamethasone acibutate; Intra-articular compound betamethasone; Intraarticular betamethasone; Phosphate and betamethasone acetate, 2 ml.;   D00244
 D00972
 D01357
 D01402
 D01637
 D02032
 D02286 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
2,
46,
65,
90,
96,
235
 13   Busulfan  13件: Busulfan; Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Fludarabine/busulfan; Busulfan iv; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, fludarabine and atg; Busulfan, fludarabine, atg, tli; Fludarabine, busulfan, thymoglobulin; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Campath, busulfan, clofarabine;   D00248   -   -   13件:
19,
20,
28,
36,
49,
51,
60,
65,
164,
274,
284,
285,
326
 14   Calcium  26件: Calcium; Calcium carbonate; Calcium levofolinate; Ascal(r) / carbasalate calcium; Calcium and cholecalciferol; Calcium citrate; Carbasalate calcium; Ethylhydrogenfumarat, calciumsalz; Ibandronate+alfacalcidol+calcium; Rosuvastatin calcium; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium rosuvastatin; Crestor tablets (calcium rosuvastatin) film-coated tablets; Calcium citrate with vitamin d2; Vidofludimus calcium; Calcium gluconate; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Low molecular weight heparin calcium injection; Amorphous calcium carbonate; Calcitriol & calcium; Calcium carbonate and alphacalcidol; Calcium lactate; Crystalline calcium supplements; Atorvastatin calcium; Calcium, dietary;   -   -   -   24件:
6,
13,
19,
46,
49,
51,
65,
68,
75,
79,
84,
93,
94,
95,
96,
97,
214,
215,
222,
224,
235,
265,
298,
299
 15   Cholecalciferol  9件: Cholecalciferol; Cholecalciferol, vitamin d3; Calcium and cholecalciferol; Cholecalciferol and c. xanthorrhiza; Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol concentrate; 5000 iu of cholecalciferol; Cholecalciferol (vitamin d3);   D00188   1件: VDR   2件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption   15件:
6,
13,
19,
20,
34,
46,
49,
53,
60,
65,
96,
97,
228,
298,
299
 16   Choline  6件: Choline; Bis-choline tetrathiomolybdate; Diazoxide choline controlled-release tablet; Choline chloride; Choline supplementation; Vitamin: choline bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1;   D07690   -   -   4件:
65,
171,
193,
299
 17   Ciclosporin  7件: Ciclosporin; Ciclosporina; Ciclosporine; Aerolised liposomal ciclosporin a; Ciclosporin (ciclosporinium); Ciclosporin a; Ciclosporine, ciclosporina;   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   44件:
11,
14,
19,
20,
26,
28,
36,
38,
39,
40,
41,
42,
45,
46,
49,
50,
53,
55,
56,
58,
60,
61,
62,
63,
64,
65,
90,
95,
97,
113,
162,
164,
222,
223,
226,
228,
234,
269,
274,
283,
284,
285,
302,
326
 18   Coenzyme M  0件:   -   -   -   9件:
13,
44,
45,
49,
51,
60,
65,
96,
164
 19   Cyclophosphamide  49件: Cyclophosphamide; Cyclophosphamide (drug); Cyclophosphamide and atg; Cyclophosphamide monohydrate; Cyclophosphamide/glatiramer acetate; Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Lenalidomide, dexamethasone and cyclophosphamide; Rituximab and cyclophosphamide iv; Prednisone, cyclophosphamide; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Cyclophosphamide-prednisone-azathioprine; Iv cyclophosphamide; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 50mg; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; Busulfan, cyclophosphamide, atg, gcsf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide post transplant; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; High-dose cyclophosphamide; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and steroids; Cyclophosphamide(ctx); Cyclophosphamide + pred; Cyclophosphamide, fludarabine; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Thalidomide, cyclophosphamide and prednisone;   D00287
 D07760 
 -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331
 20   Daclizumab  7件: Biib019 (daclizumab); Daclizumab; Daclizumab (anti-cd25 humanized monoclonal antibody); Daclizumab high yield process; Daclizumab hyp; Daclizumab hyp (dac hyp); Daclizumab with greek suufix;   D03639   1件: IL2RA   4件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, JAK-STAT signaling pathway   7件:
13,
56,
60,
65,
97,
283,
284
 21   Danazol  1件: Danazol;   D00289   3件: AR, ESR1, PGR   3件: Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation   4件:
60,
64,
65,
285
 22   Dexamethasone  35件: Dexamethasone; Dexamethasone soduim phosphate; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone, 40 mg; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Pomalidomide and dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Dexamethasone (50mg 1dd6, 3 consecutive days/month); Control intervention (no dexamethasone); Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Peri-neural dexamethasone 1 mg; Dexamethasone parotid irrigation; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone abcur; Dexamethasone and rituximab; High dose dexamethasone pulses; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate ph. eur.; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Dexamethasone 0.5mg tablet; Dexamethasone 2mg tablets; Dexamethasone 0,5mg; Bupivacaine/epinephrine/dexamethasone; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone 21-phosphate; Mmf and dexamethasone; Dexamethasone sodium phosphate 250 mg/10 ml solution;   D00292
 D00975
 D01510
 D01615
 D01632
 D01948
 D02174
 D02591
 D02592 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   20件:
13,
16,
28,
35,
46,
53,
63,
65,
70,
74,
75,
81,
83,
84,
90,
96,
97,
222,
296,
299
 23   Durvalumab  1件: Durvalumab;   D10808   1件: CD274   2件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer   1件:
65
 24   Eflornithine  4件: Eflornithine; Eflornithine plus nifurtimox combination therapy; Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d; Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d;   D07883   1件: ODC1   2件: Arginine and proline metabolism, Glutathione metabolism   1件:
65
 25   Elapegademase  2件: Elapegademase; Elapegademase-lvlr;   D11017   -   -   1件:
65
 26   Eltrombopag  9件: Eltrombopag; Eltrombopag 12.5 mg; Eltrombopag 25 mg; Eltrombopag olamine; Hatg/csa /eltrombopag -cohort 1; Hatg/csa /eltrombopag cohort 2; Hatg/csa /eltrombopag cohort 3; Eltrombopag olamine (sb-497115-gr); Eltrombopag oral tablets;   D03978   -   -   4件:
60,
63,
65,
285
 27   Ethanol  14件: Endocannabinoid palmitoylethanolamide (pea); Palmitoylethanolamide; Treprostinil diethanolamine; Ut-15c (treprostinil diethanolamine); Ut-15c sr (treprostinil diethanolamine); Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; Ethanolamine; Ethanolamine oleate;   D00068
 D02798
 D04855
 D06542 
 -   -   49件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
58,
61,
63,
64,
65,
66,
81,
84,
85,
86,
88,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
279,
280,
283,
284,
285,
288,
298,
299,
300,
331
 28   Etoposide  2件: Etoposide; Carmustine, etoposide, cytarabine, and melphalan (beam);   D00125
 D04107 
 -   -   11件:
11,
13,
14,
26,
28,
34,
60,
65,
85,
164,
331
 29   Fexinidazole  2件: Fexinidazole; Tablets fexinidazole;   D11252   -   -   1件:
65
 30   Fibrinogen Human  0件:   -   -   -   3件:
14,
65,
288
 31   Filgrastim  7件: Filgrastim; Pegfilgrastim; Ep2006 (filgrastim); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); Filgrastim (g-csf);   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   28件:
2,
6,
13,
16,
25,
26,
28,
34,
35,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
85,
96,
113,
164,
283,
284,
285,
331
 32   Fludarabine  23件: Fludarabine; Fludarabine phosphate; Fludarabine monophosphate; Sq fludarabine; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Fludarabine (flu); Fludarabine, cyclophosphamide; Fludarabine/ melphalan; Fludarabine/busulfan; Busulfan, fludarabine and atg; Busulfan, fludarabine, atg, tli; Campath, fludarabine, cyclophosphamide; Fludarabine phosphate 30 mg; Fludarabine phosphate 40 mg; Fludarabine, busulfan, thymoglobulin; Fludarabine, melphalan, thiotepa; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; Cyclophosphamide, fludarabine; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen);   D01907
 D07966 
 1件: RRM1   2件: Purine metabolism, Pyrimidine metabolism   17件:
13,
28,
36,
46,
49,
51,
60,
61,
62,
65,
85,
96,
164,
283,
284,
285,
326
 33   Fucose  2件: Fucose; L-fucose;   -   -   -   1件:
65
 34   Gadolinium  6件: Gadolinium; Gadolinium-based contrast; Standard gadolinium contrast; Gadolinium contrast; Gadolinium for abdomen; Gadolinium for lower back;   -   -   -   6件:
13,
34,
46,
58,
65,
305
 35   Glycolic acid  1件: Glycolic acid;   -   -   -   1件:
65
 36   Human C1-esterase inhibitor  0件:   -   -   -   1件:
65
 37   Human interleukin-2  3件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2); Anti-human interleukin-23 monoclonal antibody;   -   -   -   14件:
2,
13,
35,
46,
49,
51,
55,
56,
63,
65,
95,
96,
97,
271
 38   Hyaluronidase  7件: Daratumumab co-formulated with recombinant human hyaluronidase (rhuph20); Hyaluronidase; Recombinant human hyaluronidase; Recombinant human hyaluronidase (rhuph20); Recombinant human hyaluronidase (rhuph20)+ immune globulin intravenous (igiv); Recombinant human hyaluronidase + immune globulin intravenous; Rituximab or rituximab hyaluronidase human;   D04455
 D04456
 D06604 
 -   -   3件:
28,
65,
331
 39   Hydroxyurea  1件: Hydroxyurea;   D00341   1件: RRM2   4件: Glutathione metabolism, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway   8件:
3,
13,
19,
20,
65,
85,
86,
284
 40   Ibuprofen  5件: Ibuprofen; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; Ibuprofen pch tablet 600mg; Ibuprofen 200mg;   D00126
 D01122
 D04490
 D06606 
 2件: PTGS1, PTGS2   1件: Arachidonic acid metabolism   6件:
13,
46,
65,
113,
271,
299
 41   Immune Globulin Human  0件:   -   -   -   20件:
2,
11,
13,
14,
17,
18,
35,
38,
39,
43,
45,
49,
50,
51,
63,
65,
85,
164,
296,
309
 42   Infliximab  66件: Infliximab; Infliximab [infliximab biosimilar 3]; Topical infliximab; Remicaide (infliximab); Abp 710 - biosimilar to infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 3 mg/kg; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-eu; Infliximab-pfizer; Innovator infliximab; Methotrexate + infliximab; Remicade (infliximab); Remicade® (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); Intravitreal infliximab; 99m technetium infliximab; 99mtc-infliximab; Inflectra (infliximab); Adalimumab and infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Ct-p13 sc (infliximab); Infliximab (ifx alone); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab 20 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab-biosimilar; Infliximab-innovator; Cyclosporine vs infliximab; Infliximab (ifx); Adalimumab, etanercept, golimumab or infliximab; Infliximab (bcd-055); Infliximab and mtx;   D02598   1件: TNF   9件: Adipocytokine signaling pathway, Antigen processing and presentation, Apoptosis, Cytokine-cytokine receptor interaction, Inflammatory bowel disease (IBD), MAPK signaling pathway, Osteoclast differentiation, Rheumatoid arthritis, TGF-beta signaling pathway   23件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
85,
95,
96,
97,
98,
162,
164,
269,
271
 43   Interferon gamma-1b  2件: Interferon gamma-1b; Interferon gamma-1b (actimmune);   D00747   2件: IFNGR1, IFNGR2   4件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer   7件:
65,
85,
90,
228,
299,
301,
326
 44   Itraconazole  2件: Itraconazole; Itraconazole/voriconazole;   D00350   -   -   4件:
3,
65,
227,
299
 45   Lenograstim  3件: Lenograstim; Granocyte - 34 million iu (lenograstim rhug-csf); Granocyte lenograstim;   D03247   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   3件:
2,
57,
65
 46   Mecasermin  2件: Mecasermin; Mecasermin [rdna origin] 10mg/ml solution;   D03297
 D04870 
 2件: GHR, IGF1R   1件: PI3K-Akt signaling pathway   6件:
65,
78,
96,
168,
265,
299
 47   Melarsoprol  3件: Melarsoprol; Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d; Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;   D00832   -   -   1件:
65
 48   Melphalan  8件: Melphalan; Carmustine, etoposide, cytarabine, and melphalan (beam); Melphalan, thalidomide and dexamethasone; Propylene glycol-free melphalan hydrochloride; Fludarabine/ melphalan; Melphalan hydrochloride; Fludarabine, melphalan, thiotepa; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D00369   -   -   14件:
11,
13,
14,
19,
20,
28,
60,
62,
65,
96,
164,
234,
284,
285
 49   Methotrexate  81件: Methotrexate; Intrathecal methotrexate; Methotrexate treatment; Mycophenolate mofetil,methotrexate; Methotrexate 2.5 mg; Methotrexate 25 mg; Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Bms-582949 and methotrexate; Certolizumab pegol + methotrexate (mtx); Cp-690,550 + methotrexate; Etanercept + methotrexate; Etanercept , methotrexate; Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate as methotrexate disodium; Methotrexate capsules; Methotrexate disodium; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Methotrexate and folic acid; Methotrexate lachema 5inj. sol; Etanercept, methotrexate, prednisolone; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Azathioprine or methotrexate; Early immunosuppressants (azathioprine, methotrexate); Methotrexate bellon; Methotrexate bellon 25mg/ml; Clobetasol propionate + methotrexate; Treatment with systemic therapy (methotrexate); Cyclosporin, methotrexate (gvhd prophylaxis);   D00142
 D02115 
 2件: DHFR, DHFR2   2件: Folate biosynthesis, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331
 50   Methylprednisolone  29件: Methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Infliximab, methylprednisolone, methotrexate; Methotrexate + methylprednisolone; Administration of rituximab and methylprednisolone; Methylprednisolone (mp); Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Intravenous methylprednisolone; Intravenous (i.v.) methylprednisolone 1000 mg, total 9;   D00407
 D00751
 D00979
 D05000
 D05001
 D05002 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296
 51   Mycophenolate mofetil  17件: Mycophenolate mofetil; Mycophenolate mofetil (cellcept); Mycophenolate mofetil [cellcept]; Mycophenolate mofetil (mmf) 3 g/day; Mycophenolate mofetil 2 g/day; Cellcept (mycophenolate mofetil); Mycophenolate mofetil,methotrexate; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Mycophenolate mofetil (mmf); Mycophenolate mofetil plus lower dose of prednisone; Azathioprine or mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (bid); Mycophenolate mofetil, low dose steroid; Prednisolone and mycophenolate mofetil; Mycophenolate mofetil(mmf); Cyclosporine combine with mycophenolate mofetil; Prednisone and mycophenolate mofetil;   D00752
 D05094
 D05095 
 2件: IMPDH1, IMPDH2   1件: Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300
 52   Mycophenolic acid  2件: Mycophenolic acid; Mycophenolic acid mofetil;   D05096   2件: IMPDH1, IMPDH2   1件: Purine metabolism   34件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
228,
234,
283,
284,
285,
300
 53   Neopterin  1件: Neopterin;   -   -   -   1件:
65
 54   Nifurtimox  5件: Eflornithine plus nifurtimox combination therapy; Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d; Nifurtimox; Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d; Nifurtimox-eflronithine combination treatment (nect);   D00833   -   -   1件:
65
 55   Omalizumab  3件: Omalizumab; Omalizumab (xolair); Rituximab combined with omalizumab;   D05251   1件: FCER1A   2件: Asthma, Fc epsilon RI signaling pathway   6件:
53,
65,
98,
162,
226,
299
 56   Palifermin  1件: Palifermin;   D05338   1件: FGFR2   2件: Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells   4件:
13,
38,
39,
65
 57   Pantoprazole  1件: Pantoprazole;   D02593
 D05353 
 2件: ATP4A, ATP4B   2件: Collecting duct acid secretion, Gastric acid secretion   2件:
13,
65
 58   Pegademase  2件: Elapegademase; Elapegademase-lvlr;   D05384   -   -   1件:
65
 59   Pentamidine  1件: Pentamidine;   D00834
 D08333 
 -   -   1件:
65
 60   Phosphate ion  0件:   -   -   -   29件:
2,
3,
11,
12,
13,
28,
36,
46,
49,
51,
53,
60,
62,
65,
70,
78,
81,
83,
90,
96,
97,
164,
235,
256,
283,
284,
285,
286,
299
 61   Pioglitazone  6件: Pioglitazone; Pioglitazone and tretinoin; Tretinoin and pioglitazone hcl; Actos (pioglitazone); Pioglitazone 15 mg; Pioglitazone or metformin;   D00945
 D08378 
 1件: PPARG   2件: AMPK signaling pathway, PPAR signaling pathway   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299
 62   Plerixafor  3件: Plerixafor; Plerixafor for conditioning before hsct.; Plerixafor mobilization of autologous cd117 stem cells;   D08971   1件: CXCR4   3件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Pathways in cancer   4件:
51,
65,
285,
299
 63   Posaconazole  2件: Posaconazole; Posaconazole (psz);   D02555   -   -   3件:
60,
65,
299
 64   Prednisolone  74件: Prednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methyloprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Peg-liposomal prednisolone sodium phosphate; Prednisolone sodium phosphate; Prednisone/prednisolone; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Intravenous methyl prednisolone; Methyl prednisolone; Methylprednisolone (or other glucocorticoid); Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; Infliximab, methylprednisolone, methotrexate; Long-circulating liposomal prednisolone; Methotrexate + methylprednisolone; Methotrexate - etanercept - prednisolone arm; Overencapsulated prednisolone tablets; Paroxetine & prednisolone; Paroxetine hydrochloride 10 & 20 mg and prednisolone 1 mg bp; Prednisolone & dipyridamole; Prednisolone 20 mg; Prednisolone 40 mg; Prednisolone 5 mg; Prednisolone tablets bp; Prednisolone tablets usp 5 mg; Prednisolone-dipyridamole; Sulphasalazine + hydroxychloroquine or prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Z102 (prednisolone and dipyridamole).; Corticosteroids (prednisone or prednisolone); Oral prednisolone; Administration of rituximab and methylprednisolone; Prednisolone and taper; Etanercept, methotrexate, prednisolone; Methylprednisolone (mp); Prednisolone + mabthera; Corticosteroid treatment (methylprednisolone or prednisolone); Methylprednisolone or prednisolone; Methylprednisolone (mp) or prednisone (pred); Methylprednisolone mylan générique; Methylprednisolone pulse; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Prednisone or prednisolone; Azd4017 and prednisolone; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Prednisolone 1mg tablets; Prednisolone 5mg tablet; Glucocorticoid (prednisone or prednisolone); Low dose prednisolone; Medium dose prednisolone; Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Corticosteroid (prednisolone); Prednisolone sodium succinate; Methylprednisolone or budesonide; Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisolone sodium metasulphobenzoate; Prednisolone tablets b.p. 5mg; Intravenous methylprednisolone; Pyridoxine plus prednisolone; Soluble prednisolone tablets; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil;   D00472
 D00980
 D00981
 D00982
 D01239
 D01998
 D02156
 D03301 
 1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300
 65   Prednisone  59件: Prednisone; Prednisone - azathioprine; Prednisone alone; Granulocyte-colony stimulating factor (g-csf) and prednisone; Prednisone/prednisolone; Prednisone acetate; Prednisone, cyclophosphamide; Over encapsulated prednisone; Prednisone and ustekinumab treatment; Prednisone capsules; Prednisone tablets usp, 1 mg; Prednisone tablets usp, 2.5 mg; Prednisone tablets usp, 5 mg; Prednisone tablets, usp; Prednisone therapy and pharmacokinetic; Prednisone treatment; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Prednisone, methylprednisolone,cyclophosphamides; Prednisone (and methylprednisolone); 0 mg prednisone; 5 mg prednisone; Methylprednisone; Prednisone 15 mg; Prednisone 5 mg; Prednisone 7.5 mg; Rayos (delayed-release prednisone); Corticosteroids (prednisone or prednisolone); Cyclophosphamide-prednisone-azathioprine; Oral prednisone 5mg; Prednisone discontinuation; Chinese herb prescription granule plus prednisone; Enalapril valsartan methylprednisone; Hormone (prednisone); Leflunomide 20 mg+prednisone 0.5mg/kg/d; Methylprednisolone (mp) or prednisone (pred); Mycophenolate mofetil plus lower dose of prednisone; Prednisone + inhibace/cozaar; Prednisone and cyclophosphamide; Prednisone arrow 20mg; Prednisone arrow 5 mg; Prednisone in full dose; Prednisone or prednisolone; Prednisone plus cyclophosphamide; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Glucocorticoid (prednisone or prednisolone); Hydroxychloroquine + prednisone; Azathioprine/prednisone; 5-asa, prednisone, azathioprine or remicade; 5-aminosalicylic acid(5-asa) and/or prednisone; Treatment systemic therapy (prednisone); Treatment with systemic therapy (prednisone); Prednisone 0,5 mg/kg orally on alternate days; Prednisone, fk506, mmf; Tacrolimus combined with prednisone; Prednisone acetate tablets; Oral prednisone; Sotatercept with prednisone boost; Prednisone and mycophenolate mofetil; Thalidomide, cyclophosphamide and prednisone;   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   44件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
145,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331
 66   Pyrimethamine  2件: Pyrimethamine; Fansidar (pyrimethamine and sulfadoxine);   D00488   -   -   4件:
2,
4,
19,
65
 67   Rabbit  16件: Antithymocyte immunoglobulin (rabbit); Rabbit; Rabbit human t lymphocyte immunoglobulin; Rabbit anti-thymocyte globulin; Rabbit antithymocyte globulin; Anti-human t-lymphocyte immunoglobulin from rabbits; Anti-thymocyte globulin, rabbit; Anti-thymocyte globulin (rabbit); Antithymocyte globulin (rabbit); Cyclophosphamide, fludarabine, rabbit atg; Rabbit anti-thymocyte globulin (atg); Rabbit antithymoglobulin (atg); Rabbit atg; Rabbit atg, (genzyme); Rabbit atg, cyclosporine, levamisole; Rabbit atg, thymoglobuline (genzyme);   -   -   -   7件:
13,
49,
51,
60,
65,
96,
285
 68   Ranitidine  1件: Ranitidine;   D00422
 D00673 
 1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   2件:
13,
65
 69   Rifaximin  10件: Rifaximin; Rifaximin 550 mg; Rifaximin delayed release (dr); Rifaximin delayed release 400 mg film coated tablet; Rifaximin delayed release tablets; Rifaximin eir; Rifaximin+omeprazole+miralax; Rifaximin-eir; Rifaximina; Rifaximin oral tablet;   D02554   -   -   7件:
6,
65,
94,
96,
97,
99,
296
 70   Rituximab  52件: Rituximab; Rituximab (rituxan); Mabthera (rituximab); Mabthera or biosimilar rituximab product; Rituximab infusion; Rituximab it; Rituximab iv; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Rituximab (mabthera® or rituxan®).; Rituximab and cyclophosphamide iv; Rituximab (arm a); Rituximab (arm b); Abatacept, rituximab or tocilizumab; Abp 798 - biosimilar to rituximab; Gp2013 - a proposed biosimilar rituximab; Idec-c2b8 (rituximab); Mabthera® (rituximab); Originator rituximab - rituxan ® or mabthera ®; Rituxan (inn: rituximab), brand name in the united states; Rituxan® (rituximab); Rituximab - mabthera; Rituximab [mabthera/rituxan]; Rituximab [mabthera]; Rituximab mabthera; Rituximab, mtx, folic acid; Rituximab, observational study amon patients with active ra; Rituximab-eu+ rituximab-pfizer x 2 courses; Rituximab-pfizer (pf-05280586) x 3 courses; Rituximab-us + rituximab-pfizer x 2 courses; Sait101 (proposed rituximab biosimilar); Individualized dose of rituximab; Rituxan (rituximab); Standard dose of rituximab; Administration of rituximab and methylprednisolone; Rituximab (anti-cd20); Alemtuzumab and rituximab; Bendamustine, rituximab; Mabthera or biosimilar rituximab; Rituximab (mabthera®); Alemtuzumab, rituximab; Dexamethasone and rituximab; Rhtpo in combination with rituximab; Immunosuppressive treatment (eg, rituximab); Rituximab (rtx) and azathioprine (aza); Intravenous rituximab; Combined plasma exchange (pex), rituximab, and corticosteroids; The standard steroid treatment, plasma exchange and rituximab; Rituximab 1g iv; Rituximab combined with omalizumab; Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab); Rituximab/ mabthera; Rituximab or rituximab hyaluronidase human;   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331
 71   Roxadustat  1件: Roxadustat;   D10593   3件: EGLN1, EGLN2, EGLN3   1件: HIF-1 signaling pathway   1件:
65
 72   SCYX-7158  1件: Scyx-7158;   -   -   -   1件:
65
 73   Sirolimus  16件: Sirolimus; Temsirolimus; Temsirolimus tablets; Sirolimus 2 mg; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Sirolimus (formerly known as rapamycin); Sirolimus 2%; Sirolimus, 2%; Rapamycin, sirolimus; Sirolimus and hydroxychloroquine; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 0,1% crème; Sirolimus oral liquid product 1mg/ml; Topical 0.1% sirolimus;   D00753   1件: MTOR   2件: Pathways in cancer, mTOR signaling pathway   36件:
2,
13,
15,
17,
34,
35,
36,
46,
49,
51,
60,
61,
62,
63,
65,
66,
67,
85,
86,
89,
96,
98,
137,
157,
158,
192,
222,
256,
277,
278,
279,
280,
281,
283,
285,
331
 74   Sulfadoxine  2件: Fansidar (pyrimethamine and sulfadoxine); Sulfadoxine;   D00580   -   -   1件:
65
 75   Tacrolimus  13件: Tacrolimus; Tacrolimus capsule; Interferon beta-1b and tacrolimus; Non-mtx dmards (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin); Tacrolimus (prograf®); Tacrolimus with methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Lcp-tacro (tacrolimus); Rectal tacrolimus; Tacrolimus capsules; Tacrolimus combined with prednisone; Tacrolimus and mmf; Tacrolimus prolonged-release hard capsules;   D00107
 D08556 
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   7件: Cellular senescence, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Osteoclast differentiation, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation   30件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
86,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299
 76   Tadekinig alfa  1件: Tadekinig alfa;   -   -   -   1件:
65
 77   Teriparatide  4件: Teriparatide; Teriparatide [rdna origin] contains recombinant human parathyroid hormone (1-34); Teriparatide (forteo); Teriparatide pen injector;   D06078   1件: PTH1R   3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action   7件:
46,
65,
68,
70,
71,
235,
274
 78   Thalidomide  9件: Thalidomide; Thalidomide (drug); Fpf 300 (thalidomide); Melphalan, thalidomide and dexamethasone; Thalidomide pharmion; Thalidomide celgene - 50 mg capsula rigida - uso orale - blister (pvc/pe/aclar/alu) 28 capsule; Thalidomide 100mg; Thalidomide 150mg; Thalidomide, cyclophosphamide and prednisone;   D00754   1件: TNF   4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, NF-kappa B signaling pathway, TNF signaling pathway   18件:
2,
16,
20,
28,
49,
51,
53,
65,
84,
85,
94,
96,
97,
227,
271,
280,
298,
331
 79   Thiotepa  5件: Thiotepa; Thiotepa--escalated dose; Thiotepa--single daily dose; Fludarabine, melphalan, thiotepa; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan;   D00583   -   -   11件:
13,
19,
20,
28,
51,
60,
65,
85,
96,
164,
284
 80   Tremelimumab  1件: Tremelimumab;   D06657   1件: CTLA4   2件: Cell adhesion molecules (CAMs), T cell receptor signaling pathway   2件:
65,
96
 81   Treosulfan  3件: Treosulfan; Ovastat 1000 (treosulfan injection); Ovastat 5000 (treosulfan injection);   D07253   -   -   3件:
13,
19,
65
 82   Ustekinumab  32件: Ustekinumab; Prednisone and ustekinumab treatment; Ustekinumab (approximately 6 mg/kg); Ustekinumab 90 milligram (mg); Ustekinumab iv; Ustekinumab sc; Ustekinumab 6 mg/kg; Ustekinumab 90 mg; Subcutaneous ustekinumab; Stelara (ustekinumab); Ustekinumab liquid in prefilled syringe; Ustekinumab 180 mg; Ustekinumab 45 mg; Evaluation of biological predictive factors of clinical response to ustekinumab; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Placebo ustekinumab; Ustekinumab (6 mg/kg); Ustekinumab (90 mg); Ustekinumab 130 mg iv; Ustekinumab 1mg/kg (ip); Ustekinumab 3 mg/kg (ip); Ustekinumab 4.5 mg/kg; Ustekinumab 6 mg/kg (ip); Ustekinumab 90 mg (sc) group 1; Ustekinumab 90 mg (sc) group 2; Ustekinumab 90 mg sc q12w; Ustekinumab 90 mg sc q8w; Ustekinumab approximately 6 mg/kg (iv); Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp); Ustekinumab iv - responder - ustekinumab 90mg sc (mp); Ustekinumab iv infusion; Ustekinumab sc injection;   D09214   3件: IL12A, IL12B, IL23A   2件: Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway   16件:
13,
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271
 83   Valaciclovir  0件:   D00398
 D08664
 D10518 
 -   -   1件:
65
 84   Valproic Acid  3件: Valproic acid; Valproic acid (vpa); Valproic acid and levocarnitine;   D00399   6件: ABAT, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2   2件: Calcium signaling pathway, GABAergic synapse   14件:
2,
3,
5,
8,
26,
34,
65,
89,
90,
102,
222,
233,
256,
331
 85   Vorhyaluronidase alfa  0件:   D06604   -   -   3件:
14,
28,
65
 86   Water  13件: 5% glucose water solution; Water; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; 15 o water; Water for injection; 15-o labeled water; Pl 12185/0002 & pl 12185/0005(water for injection); Dextrose, 5% in water; High water intake; Lactose in water; Water for injections; Water for injections, ep;   D00001   -   -   22件:
2,
5,
6,
13,
17,
19,
28,
35,
46,
53,
57,
63,
65,
67,
78,
84,
97,
193,
226,
271,
278,
299
 87   Zoledronic acid  4件: Zoledronic acid; Zoledronic acid 5mg/bag 100ml inj; Zoledronic acid monohydrate; Lonafarnib, zoledronic acid, and pravastatin;   D01968
 D06378
 D06379
 D08689 
 1件: FDPS   1件: Terpenoid backbone biosynthesis   11件:
6,
13,
46,
65,
93,
95,
96,
271,
274,
299,
333

先頭へ